HALAVEN

This brand name is authorized in United States. It is also authorized in Australia, Austria, Brazil, Canada, Croatia, Cyprus, Ecuador, Estonia, Finland, France, Hong Kong SAR China, Ireland, Israel, Japan, Lithuania, Mexico, Netherlands, Poland, Romania, Singapore, South Africa, Spain, UK.

Active ingredients

The drug HALAVEN contains one active pharmaceutical ingredient (API):

1	Eribulin mesylate UNII AV9U0660CW - ERIBULIN MESYLATE
	Eribulin is a microtubule dynamics inhibitor belonging to the halichondrin class of antineoplastic agents. It is a structurally simplified synthetic analogue of halichondrin B, a natural product isolated from the marine sponge Halichondria okadai.
	Read more about Eribulin mesylate

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
HALAVEN Solution for injection	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01XX41	Eribulin	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01X Other antineoplastic agents → L01XX Other antineoplastic agents
Discover more medicines within L01XX41

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	10140Q, 10144X, 11199K, 11212D
BR	Câmara de Regulação do Mercado de Medicamentos	533220020002817, 542714020000002
CA	Health Products and Food Branch	02377438
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	5404-MEE-0820
EE	Ravimiamet	1523674, 1523685, 1693818, 1693829
ES	Centro de información online de medicamentos de la AEMPS	11678001
FI	Lääkealan turvallisuus- ja kehittämiskeskus	176930
FR	Base de données publique des médicaments	63816522
GB	Medicines & Healthcare Products Regulatory Agency	187724
HK	Department of Health Drug Office	61632, 65349
IL	מִשְׂרַד הַבְּרִיאוּת	6835
JP	医薬品医療機器総合機構	4291420A1022
LT	Valstybinė vaistų kontrolės tarnyba	1059639, 1059640, 1078389, 1078390
MX	Comisión Federal para la Protección contra Riesgos Sanitarios	237M2014
NL	Z-Index G-Standaard, PRK	126713, 98809
PL	Rejestru Produktów Leczniczych	100285229
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W67329001, W67329002
SG	Health Sciences Authority	13917P
US	FDA, National Drug Code	43624-002, 62856-389
ZA	Health Products Regulatory Authority	48/20.2.8/0047